- Home
- LQDA vs BOOT Comparison
LQDA vs BOOT Comparison
Compare LQDA & BOOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LQDA | BOOT |
|---|---|---|
| Founded | 2004 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Clothing/Shoe/Accessory Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.5B |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LQDA | BOOT |
|---|---|---|
| Price | $91.70 | $166.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 12 |
| Target Price | $41.00 | ★ $223.09 |
| AVG Volume (30 Days) | ★ 1.3M | 738.6K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.81 | 25.00 |
| EPS | 0.52 | ★ 2.29 |
| Revenue | $158,320,000.00 | ★ $776,854,000.00 |
| Revenue This Year | $278.87 | $19.98 |
| Revenue Next Year | $57.13 | $13.91 |
| P/E Ratio | $173.50 | ★ $71.44 |
| Revenue Growth | ★ 1031.18 | 14.59 |
| 52 Week Low | $21.15 | $133.18 |
| 52 Week High | $91.57 | $210.25 |
Technical Indicators
Market Signals| Indicator | LQDA | BOOT |
|---|---|---|
| Relative Strength Index (RSI) | 67.21 | 58.98 |
| Support Level | $31.99 | $158.75 |
| Resistance Level | N/A | $170.63 |
| Average True Range (ATR) | 5.09 | 6.33 |
| MACD | 0.15 | 1.98 |
| Stochastic Oscillator | 99.45 | 82.34 |
Price Performance
Historical ComparisonAbout LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
About BOOT Boot Barn Holdings Inc.
Boot Barn Holdings Inc operates specialty retail stores that sell western and work boots and related apparel and accessories. The Company operates retail locations throughout the U.S. and sells its merchandise via the Internet. The Company operates a total of approximately 539 stores in 49 states. All stores operated under the Boot Barn name.